BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

DSM Pharmaceutical Products to Supply Cancer Drug for Eisai Inc. (ESALF.PK)


3/5/2013 7:40:34 AM

PARSIPPANY, N.J., March 5, 2013 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE/Euronext: DSM KON), today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products. The agreement covers the production of eribulin mesylate as well as other developmental drugs. Alexander Wessels, President and CEO of DSM Pharmaceutical Products, stated, "We are delighted to be working with Eisai under a long-term agreement to serve markets globally for important human health treatments, bringing our expertise and reliability in sterile injectables and worldwide regulatory record to ensure market supply."

DSM will be a supplier for eribulin mesylate to the US market. Commercial production is anticipated to start in early 2013. Laura Parks, President, DSM Pharmaceuticals, Inc., the finished dosage business of DSM, stated, "It has been an honor to work with Eisai through the launch into commercial supply of eribulin mesylate and to continue to support the development of other products. Combining the expertise of Eisai in developing innovative medicines with DSM's strength in Good Manufacturing Practices (GMP),and supply chain management will provide critical high quality treatments for patients."

DSM operates a 1.5 million square foot finished dosage facility in Greenville, North Carolina, USA, with a broad range of capabilities in aseptic filling of liquid and freeze-dried cytotoxic and non-cytotoxic steriles, the manufacture of tablets and capsules, pharmaceutical development services, and clinical trial materials manufacturing for solid and injectable forms, and holds a range of regulatory approvals including the production of scheduled drugs.

Eisai is a research based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. "Eisai appreciates the focus and effort the DSM Pharmaceuticals team in Greenville has provided in support of our commercial and developmental products. We are particularly pleased to have received FDA approval to manufacture eribulin mesylate at DSM for the commercial US market. This alternate site of manufacturing strengthens the supply reliability of this important product for our patients," added Shawn Gallagher, President Partnership Management CFU, Eisai Inc.

No financial details were disclosed.

DSM Bright Science. Brighter Living.
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 23,500 employees deliver annual net sales of around EUR 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com/pharma

For more information:

Guy Tiene

Director, Marketing and Communications

tel. +1 973 257 8160

email guy.tiene@dsm.com

Laura Parks

President, DSM Pharmaceuticals, Inc.

tel. +1 252 707 7620

email laura.parks@dsm.com

SOURCE DSM Pharmaceutical Products



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES